Immunic (IMUX) Price & Analysis

Compare

1,701 Followers

IMUX Stock Chart & Stats

Day’s Range― - ―

52-Week Range$0.56 - $2.11

Previous CloseN/A

Volume261.21K

Average Volume (3M)1.04M

Market Cap

$84.07M

Enterprise Value$37.86M

Total Cash (Recent Filing)$55.31M

Total Debt (Recent Filing)$979.00K

Price to Earnings (P/E)―

Beta1.34

Next Earnings

Nov 06, 2025

EPS Estimate

-0.16

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.20

Shares Outstanding98,650,590

10 Day Avg. Volume985,844

30 Day Avg. Volume1,038,362

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.45

Enterprise Value/Revenue332.12

Enterprise Value/Gross Profit-1.31K

Enterprise Value/Ebitda-0.36

Forecast

1Y Price Target

$6.33

Price Target Upside588.04% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

Bulls Say, Bears Say

Bulls Say

Clinical EfficacyVidofludimus calcium demonstrated a reduced relative risk of 24-week confirmed disability worsening events by 20% compared to placebo for the overall study population.

Clinical Trial ProgressThe completion of enrollment for the Phase 3 ENSURE program in relapsing MS indicates progress and sets the company on track for future data releases.

Bears Say

Competitive PressureThe upcoming competitor data from the PERSEUS study for the BTK inhibitor tolebrutinib in PPMS, despite its liver toxicity liabilities, could impact the competitive landscape.

Financial ConcernsLimited cash runway suggests the necessity for business development to unlock value.

Immunic News

Immunic reports Q2 EPS (20c), consensus (16c)

“During the second quarter and more recently, we have made substantial clinical progress in advancing our potentially transformative...

8d ago

IMUX

Promising Efficacy and Safety of Vidofludimus Calcium in MS Trials Reinforces Buy Rating

Analyst Matthew Caufield from H.C. Wainwright reiterated a Buy rating on Immunic and keeping the price target at...

3d ago

IMUX

Immunic, Inc. Advances Multiple Sclerosis Drug Trials

Immunic, Inc. ( ($IMUX) ) has released its Q2 earnings. Here is a breakdown of the information Immunic,...

7d ago

IMUX

Immunic Advances Phase 3 Trials and Financial Health

Immunic ( ($IMUX) ) just unveiled an announcement. Immunic, Inc. announced significant progress in its clinical trials and...

8d ago

IMUX

Immunic announces vidofludimus calcium trial data

Building on the recently released data showing reductions in the relative risk of 24-week confirmed disability worsening events...

2M ago

IMUX

Immunic completes enrollment for both ENSURE trials

Immunic (IMUX) announced the completion of enrollment for both phase 3 ENSURE trials of lead asset, nuclear receptor-related...

2M ago

IMUX

Immunic Approves Equity Plan Amendment at Annual Meeting

Immunic ( ($IMUX) ) has shared an update. On June 4, 2025, Immunic, Inc. held its annual stockholders’...

2M ago

IMUX

Immunic Announces $65 Million Public Offering

Immunic ( ($IMUX) ) has provided an update. On May 28, 2025, Immunic, Inc. announced an underwritten public...

3M ago

IMUX

Immunic price target lowered to $10 from $17 at D. Boral Capital

D. Boral Capital lowered the firm’s price target on Immunic (IMUX) to $10 from $17 and keeps a...

3M ago

IMUX

Immunic announces pricing of $65M public offering

Immunic (IMUX) announced the pricing of an underwritten public offering of (i) pre-funded warrants to purchase shares of...

3M ago

IMUX

Immunic Announces Public Offering to Fund Trials

Immunic ( ($IMUX) ) has shared an update. On May 28, 2025, Immunic, Inc. announced the commencement of...

3M ago

IMUX

Immunic announces offering of warrants to purchase common stock

Immunic (IMUX) announced that it has commenced an underwritten public offering of (i) pre-funded warrants to purchase shares...

3M ago

IMUX

Immunic price target lowered to $5 from $6 at B. Riley

B. Riley analyst William Wood lowered the firm’s price target on Immunic (IMUX) to $5 from $6 and...

3M ago

IMUX

Buy Rating Affirmed for Immunic’s Vidofludimus Calcium Due to Promising Phase 2 Results and Strong MS Treatment Potential

Analyst Matthew Caufield of H.C. Wainwright reiterated a Buy rating on Immunic (IMUX – Research Report), retaining the...

3M ago

IMUX

IMUX FAQ

What was Immunic, Inc.’s price range in the past 12 months?

Immunic, Inc. lowest stock price was $0.56 and its highest was $2.11 in the past 12 months.

What is Immunic, Inc.’s market cap?

Immunic, Inc.’s market cap is $84.07M.

When is Immunic, Inc.’s upcoming earnings report date?

Immunic, Inc.’s upcoming earnings report date is Nov 06, 2025 which is in 83 days.

How were Immunic, Inc.’s earnings last quarter?

Immunic, Inc. released its earnings results on Aug 07, 2025. The company reported -$0.2 earnings per share for the quarter, missing the consensus estimate of -$0.158 by -$0.042.

Is Immunic, Inc. overvalued?

According to Wall Street analysts Immunic, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Immunic, Inc. pay dividends?

Immunic, Inc. does not currently pay dividends.

What is Immunic, Inc.’s EPS estimate?

Immunic, Inc.’s EPS estimate is -0.16.

How many shares outstanding does Immunic, Inc. have?

Immunic, Inc. has 98,650,590 shares outstanding.

What happened to Immunic, Inc.’s price movement after its last earnings report?

Immunic, Inc. reported an EPS of -$0.2 in its last earnings report, missing expectations of -$0.158. Following the earnings report the stock price went down -8.163%.

Which hedge fund is a major shareholder of Immunic, Inc.?

Currently, no hedge funds are holding shares in IMUX

Immunic Stock Smart Score

Neutral

Fundamentals

Return on Equity

-208.93%

Trailing 12-Months

Asset Growth

-28.98%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Immunic, Inc.

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.

Immunic (IMUX) Earnings & Revenues

Historic Earnings Reports

IMUX Stock 12 Month Forecast

Average Price Target

$6.33

▲(588.04% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","8":"$8","11":"$11","-1":"-$1"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":10,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$10.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.33,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$6.33</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,2,5,8,11],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.93,1.6276923076923078,2.3253846153846154,3.0230769230769234,3.720769230769231,4.418461538461538,5.116153846153846,5.813846153846153,6.5115384615384615,7.2092307692307696,7.906923076923077,8.604615384615386,9.302307692307693,{"y":10,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.93,1.3453846153846154,1.7607692307692309,2.1761538461538463,2.5915384615384616,3.0069230769230773,3.4223076923076925,3.837692307692308,4.253076923076923,4.668461538461538,5.083846153846154,5.49923076923077,5.914615384615384,{"y":6.33,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.93,1.166153846153846,1.4023076923076923,1.6384615384615384,1.8746153846153846,2.1107692307692307,2.3469230769230767,2.583076923076923,2.819230769230769,3.0553846153846154,3.2915384615384613,3.5276923076923077,3.7638461538461536,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.4,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.51,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.59,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.19,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.4,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.98,"date":1738368000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.19,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.06,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.17,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.7,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.69,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.93,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >